Non-Hodgkin's lymphoma involving the adrenal glands and the central nervous system (CNS): a particular evolution after chemotherapy. Ann Endocrinol (Paris) 2005;66:527-531.Velayoudom FL, Cardot-Bauters C, Decouvelaere AV, Vlaeminck V, Bauters F, Wemeau JL. Non Hodgkin's lymphoma involving...
Low-grade malignant non-Hodgkin's lymphomaMultidrug therapyTotal body irradiationClinical resultsBetween January, 1977, and September, 1978, 14 stage III and 7 stage IV patients with previously untreated non-Hodgkin's lymphoma were selected for low-dose fractionated total body irradiation (TBI), 150...
The results of autografting in patients with relapsed low grade non-Hodgkin''s Lymphoma (NHL) have generally been disappointing due to the failure to maintain remission and the late development of myelodysplasia. Most series have used regimens that include total body irradiation and purged stem cel...
[30]Schneider U, Schwenk HU, Bornkamm G (1977) Characterization of EBV-genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 19: 621–626. Available: http://www.ncbi.nlm.nih.gov/pub...
The clinical application of rituximab (chimeric mouse anti-human CD20 mAb, Rituxan, IDEC-C2B8), alone and/or combined with chemotherapy, has significantly ameliorated the treatment outcome of patients with relapsed and refractory low-grade or follicular non-Hodgkin's lymphoma (NHL). The exact in ...
Keywords: Acute lymphoblastic leukemia, CD22, Inotuzumab ozogamicin, Non-Hodgkin lymphoma, Antibody-drug conjugate, ADC Introduction The prognosis of adults with relapsed /refractory (R/R) acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) is still very poor [1–5]. With the in-...
Leuk LymphomaHaim N, Leviov M, Ben-Arieh Y, et al. : Intermediate and high-grade gastric non-Hodgkin’s lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy . Leuk Lymphoma 1995, 17 :321–326. This is the best prospective evaluation...
Tasheema Prince
Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol. 2005;131:193-200.Cheung C, Burton C, Smith P, et al. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol 2...
: Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin’s lymphoma . Radiat Oncol Investig 1999, 7 :186–191.Aref A, Narayan S, Tekyi⁃Mensah S, et al. Value of radiation therapy in the management of chemoresistant intermediate grade non⁃Hodgkin' ...